Navigation Links
Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
Date:12/9/2009

red blood cells do not mold to the size of the blood vessel. They obstruct small blood vessels and can block normal red blood cells from traveling through the circulatory system limiting oxygen delivery to tissues and organs. This is known as a "sickle crisis". There are currently no approved medications to treat sickle cell crises, and only symptomatic relief is available.

The number of crises a sickle cell disease patient experiences varies. Most sickle cell disease patients experience at least one sickle crisis at some point during their lives; some may suffer 15 or more crises each year. Patients suffering from a sickle crisis experience severe pain and are at risk of stroke, heart attack or even death.

About Sangart

Sangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Based on more than a decade of research, Sangart has refined the pegylation of human hemoglobin to create a molecule, MP4, with the ability to carry oxygen through the circulatory system to prevent and treat ischemia.

To learn more about Sangart, please visit the company's website at www.sangart.com.


Media Contact:
Rachel Martin
Edelman Public Relations     Office: 323-202-1031
Rachel.Martin@edelman.com    Cell: 323-373-5556

SOURCE Sangart, Inc.


'/>"/>
SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
2. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
3. Sangart, Inc. Completes Series F Funding Round
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... --  SunTrust Robinson Humphrey (STRH) today announced ... equity research team in biotechnology and oilfield services.  ... research demonstrates our commitment to providing our valued ... investment decision making," said Biff Woodruff , ... make significant investments in differentiated content at a ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... August 27, 2014 Scientists, researchers, and ... SPIE Laser Damage 2014 symposium. Marking its ... high-power lasers will run 14-17 September. The event is ... and photonics . , The premier conference for basic ... damage to optical materials will engage researchers and engineers ...
(Date:8/28/2014)... August 28, 2014 Earlier this month, ... in partnership with the U.S. Air Force on ... The results indicated that this type of fuel made ... and will be important to America’s Eco friendly future. ... has a mandate to become independent of foreign oil ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5
... mimicking a brick-and-mortar molecular structure found in seashells, University ... strong as steel but lighter and transparent. , ... water-soluble polymer that shares chemistry with white glue. , ... but the new material isn,t quite stretchy enough to ...
... with,its third quarter 2007 earnings release (expected to be issued ... ) is pleased to invite you to,listen to its quarterly ... on Thursday, October 25 at 9:00 a.m. ET. What: ... Presentation When: October 25, 2007, 9:00 a.m. ...
... Oct. 4 Coherent, Inc.,(Nasdaq: COHR ) today ... an additional NASDAQ Staff Determination letter indicating that,the Company ... set forth in Marketplace Rules 4350(e) and 4350(g) due ... during its fiscal,year ended September 30, 2007. The notice ...
Cached Biology Technology:U-M research: New plastic is strong as steel, transparent 2Coherent, Inc. Receives Expected Letter from NASDAQ 2
(Date:8/28/2014)... are healthier for your neighbors than traditional cigarettes, ... to a new study from USC. , Scientists ... 10-fold decrease in exposure to harmful particles, with ... exposure to some harmful metals in second-hand e-cigarette ... While tobacco smoke contains high levels of polycyclic ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
(Date:8/28/2014)... developmental on-off switch for Streptomyces , a group ... the world,s naturally derived antibiotic medicines. , Their ... possible to manipulate this switch to make nature,s antibiotic ... 28 in Cell , found that a unique ... larger protein called BldD ultimately controls whether a bacterium ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... remains a devastating problem in Africa and understanding the ... the effort to combat the disease. A new study ... conducted in Western Kenya by Jacob Koella and colleagues ... with the infectious stages of malaria than to those ...
... warfarin to prevent harmful clotting after a heart attack, stroke, ... vary greatly and can be hard to predict. Some of ... involved in blood clotting, according to a new study published ... of Medicine. , By looking at the genetic makeup of ...
... of Utah researchers showed that a fruit fly gene ... into adults, and how the transformation initially proceeds. Understanding ... children become surly teenagers. , When the DHR4 gene ... an immature larva to a sexually active adult. It ...
Cached Biology News:Mosquitoes are more attracted to individuals infected with malaria 2Genetic variation alters response to common anti-clotting drug 2Genetic variation alters response to common anti-clotting drug 3Scientists find a maturity gene in fly 2Scientists find a maturity gene in fly 3Scientists find a maturity gene in fly 4
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... transporter 2 (APT2) (Peptide ... PSF2) (Peptide supply factor ... involved in antigen processing ... Antigen: Recombinant ...
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Biology Products: